1. Home
  2. XP vs PODD Comparison

XP vs PODD Comparison

Compare XP & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XP Inc.

XP

XP Inc.

N/A

Current Price

$32.13

Market Cap

10.2B

Sector

Finance

ML Signal

N/A

Logo Insulet Corporation

PODD

Insulet Corporation

N/A

Current Price

$134.78

Market Cap

10.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XP
PODD
Founded
2001
2000
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
10.2B
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
XP
PODD
Price
$32.13
$134.78
Analyst Decision
Strong Buy
Buy
Analyst Count
13
26
Target Price
$26.86
★ $170.96
AVG Volume (30 Days)
★ 10.1M
1.3M
Earning Date
11-16-2026
11-04-2026
Dividend Yield
★ 0.66%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 2.67
Revenue
N/A
★ $2,708,100,000.00
Revenue This Year
$12.99
$21.38
Revenue Next Year
$12.43
$13.68
P/E Ratio
★ $11.42
$50.36
Revenue Growth
N/A
★ 30.73
52 Week Low
$14.80
$126.40
52 Week High
$30.88
$354.88

Technical Indicators

Market Signals
Indicator
XP
PODD
Relative Strength Index (RSI) 90.31 43.94
Support Level $18.60 $127.57
Resistance Level N/A $143.45
Average True Range (ATR) 1.07 3.52
MACD 1.10 0.50
Stochastic Oscillator 98.95 46.32

Price Performance

Historical Comparison
XP
PODD

About XP XP Inc.

XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: